Morgan Stanley Backs WST as Borrow Market Loosens
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
West Pharmaceutical Services has attracted a notable analyst upgrade this week. The signals are pointing in the same direction.
Morgan Stanley Flips Bullish
Morgan Stanley upgraded WST to Overweight on September 22, raising its price target to $400 from $365. Analyst Kallum Titchmarsh's move marks a meaningful shift — the firm had held an Equal-Weight stance since at least July, when it last raised the target to $365.
The upgrade puts Morgan Stanley in line with an increasingly bullish analyst pack. UBS raised its target to $415 on September 9. Citigroup lifted to $412 in August. Evercore ISI stands at $425. The consensus mean target is now $407.56, implying roughly 9% upside from Wednesday's close of $373.60.
The buy consensus rating is backed by four Outperform ratings and one Hold. No analysts currently rate the stock a Sell.
Lending Market Signals Agreement
The borrow market is telling a similar story. Cost to borrow has dropped 51% in one week — from around 0.37% to just 0.18% as of September 24. That is the lowest level in the 30-day history shown, and down 59% over the month.
Availability stands at 4,232% — far above the 52-week minimum of 1,626%. There are roughly 59.5 million shares available to borrow against just 2.3 million shares short. Bears are not pressing the position. Short interest sits at 3.3% of free float, a modest level that has barely budged over the past month.
Earnings on the Horizon
Next earnings are scheduled for October 29. The most recent print, on July 23, saw the stock fall 8.4% on the day and another 5.3% over the following week. That creates a known near-term volatility point.
The put/call ratio currently sits at 0.84 — slightly above the 20-day mean of 0.79 but well within normal range (z-score: 0.52). Options markets are not flashing unusual hedging activity.
Data Summary
- Morgan Stanley upgrade: Equal-Weight → Overweight; target $365 → $400
- Consensus target: $407.56; 9% upside from current price
- Cost to borrow: 0.18%, down 51% in one week
- Availability: 4,232% — very loose borrow market
- SI % of Free Float: 3.3% — modest, flat over one month
- Next earnings: October 29
- Largest institutional holder: BlackRock, 9.45% (added ~101k shares)
Stocks in this article
See the live data behind this article on ORTEX.
Open WST on ORTEX →How this article was generated
- Generated
- 25 Sept 2026, 11:36
- Data as of
- 25 Sept 2026, 11:35
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.